IMMNOV Immunovia AB (publ)

0.0049USD0.0501 SEK · STO+52.28%Mkt Cap: 5.00M USDP/E: —

Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins a…

Institutional holders1 on file

Key Statistics

Company
Market Cap5.00M USD
Enterprise Value1.67M USD
Revenue (TTM)192.23K USD
Gross Profit54.04K USD
Net Income (TTM)-14.36M USD
Revenue/Share0.0003 USD
Last Price0.0049 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees19
CountrySE
SectorHealthcare
IndustryDiagnostics & Research
ISINSE0006091997
Valuation
P/E (Trailing)—
P/E (Forward)0.01
PEG—
EV/EBITDA-0.23
EV/Revenue8.71
P/S26.00
P/B5.01
EPS (TTM)-0.0059 USD
EPS (Forward)0.69 USD
52W Range
0.00307% of range0.0315
52W High0.0315 USD
52W Low0.0030 USD
Profitability
Gross Margin80.15%
Oper. Margin-3865.08%
EBITDA Margin0.00%
Profit Margin-21301.46%
ROE-225.30%
ROA-165.41%
ROIC—
ROCE-110.94%
Growth
Revenue Growth734.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.72M USD
CapEx (TTM)547.17K USD
FCF Margin-2308.76%
FCF Yield-88.79%
Net Debt-1.64M USD
Net Debt/EBITDA0.22
Net Debt/FCF—
Balance Sheet
Debt/Equity0.01
Current Ratio1.29
Quick Ratio1.26
Book Value/Sh0.0010 USD
Cash/Share0.0029 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.0423 USD
Upside (mean)+758.3%
Target Range0.0423 USD – 0.0423 USD
# Analysts1
Ownership
Shares Out.1.01B
Float619.73M
Insiders9.77%
Institutions15.95%
Technical
SMA 500.0079 (-37.6%)
SMA 2000.0155 (-68.3%)
Beta2.73
S&P 52W Chg12.00%
Avg Vol (30d)9.67M
Avg Vol (10d)10.07M
Technical Indicators
RSI (14)47.3
MACD-0.0131
MACD Signal-0.0156
MACD Hist.+0.0025
BB Upper0.0074 USD
BB Middle0.0044 USD
BB Lower0.0015 USD
BB Width134.51%
ATR (14)0.0009 USD
Vol Ratio (20d)3.74x

About Immunovia (STO: IMMNOV)

›

Immunovia (STO: IMMNOV) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 19 employees.

The shares were at 0.0501 SEK on 19 November 2026, down 83.3% over 52 weeks. Its 52-week range is 0.0300 SEK to 0.3200 SEK: the price is 84.3% below the high and 67.0% above the low.

Its market capitalisation is 50.78M SEK.

Immunovia reports return on equity of -225.3% and revenue up 734.7% year over year.

It holds more cash than debt, a net cash position of 16.69M SEK. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.